Clinical Trials in Pingxiang, Jiangxi
19 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled603 locationsNCT07037459
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled484 locationsNCT05878769
Recruiting
Phase 2
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd300 enrolled28 locationsNCT05686642
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Arthritis, Rheumatoid
Merck Sharp & Dohme LLC182 enrolled62 locationsNCT07176390
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC315 enrolled95 locationsNCT07133633
Recruiting
Phase 2
Phase II Study of RC1416 Injection in COPD
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.180 enrolled41 locationsNCT07402551
Recruiting
Phase 3
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Migraine
AbbVie1,300 enrolled149 locationsNCT06241313
Recruiting
Phase 1
A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd112 enrolled11 locationsNCT07323173
Recruiting
Phase 4
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Glucocorticoid-induced Osteoporosis
Amgen100 enrolled16 locationsNCT06588153
Recruiting
Phase 2
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
BeiGene90 enrolled29 locationsNCT07100938
Recruiting
Phase 3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Primary Sjogrens Disease
argenx580 enrolled304 locationsNCT06684847
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
Phase 3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643
Recruiting
Phase 2
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
Toll Biotech Co. Ltd. (Beijing)24 enrolled6 locationsNCT07408024
Recruiting
Phase 2
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Mabwell (Shanghai) Bioscience Co., Ltd.360 enrolled51 locationsNCT07292714
Recruiting
Phase 2
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Gout FlareAcute Gouty ArthritisGout Flares+1 more
Atom Therapeutics Co., Ltd380 enrolled38 locationsNCT07145229
Recruiting
Phase 2Phase 3
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd374 enrolled9 locationsNCT05744687
Recruiting
Phase 3
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
Asthma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.660 enrolled74 locationsNCT06829784